SG10201810928SA - Novel antitumoral use of cabazitaxel - Google Patents
Novel antitumoral use of cabazitaxelInfo
- Publication number
- SG10201810928SA SG10201810928SA SG10201810928SA SG10201810928SA SG10201810928SA SG 10201810928S A SG10201810928S A SG 10201810928SA SG 10201810928S A SG10201810928S A SG 10201810928SA SG 10201810928S A SG10201810928S A SG 10201810928SA SG 10201810928S A SG10201810928S A SG 10201810928SA
- Authority
- SG
- Singapore
- Prior art keywords
- cabazitaxel
- novel
- novel antitumoral
- prostate cancer
- antitumoral use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25616009P | 2009-10-29 | 2009-10-29 | |
| US29390310P | 2010-01-11 | 2010-01-11 | |
| US35583410P | 2010-06-17 | 2010-06-17 | |
| US35588810P | 2010-06-17 | 2010-06-17 | |
| US36992910P | 2010-08-02 | 2010-08-02 | |
| US38393310P | 2010-09-17 | 2010-09-17 | |
| US38996910P | 2010-10-05 | 2010-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810928SA true SG10201810928SA (en) | 2019-01-30 |
Family
ID=43567614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810928SA SG10201810928SA (en) | 2009-10-29 | 2010-10-27 | Novel antitumoral use of cabazitaxel |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US8927592B2 (es) |
| EP (1) | EP2493466B1 (es) |
| JP (2) | JP5566466B2 (es) |
| KR (1) | KR101712231B1 (es) |
| CN (1) | CN102770131A (es) |
| AR (1) | AR078824A1 (es) |
| AU (4) | AU2010310986A1 (es) |
| BR (1) | BR112012011457A2 (es) |
| CA (1) | CA2779009A1 (es) |
| CR (1) | CR20120204A (es) |
| DK (1) | DK2493466T3 (es) |
| EA (1) | EA024186B1 (es) |
| EC (1) | ECSP12011836A (es) |
| ES (1) | ES2862340T3 (es) |
| GT (1) | GT201200123A (es) |
| IL (3) | IL219443A0 (es) |
| MA (1) | MA33767B1 (es) |
| MX (1) | MX336339B (es) |
| MY (1) | MY164086A (es) |
| NI (1) | NI201200071A (es) |
| PE (1) | PE20121429A1 (es) |
| PL (1) | PL2493466T3 (es) |
| PT (1) | PT2493466T (es) |
| SG (1) | SG10201810928SA (es) |
| SV (1) | SV2012004192A (es) |
| TN (1) | TN2012000188A1 (es) |
| TW (2) | TWI533866B (es) |
| UY (1) | UY32987A (es) |
| WO (1) | WO2011051894A1 (es) |
| ZA (1) | ZA201203123B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
| BR112012011457A2 (pt) | 2009-10-29 | 2016-05-03 | Aventis Pharma Sa | uso antitumoral de cabazitaxel. |
| EP2688877B1 (en) * | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
| JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| US9403785B2 (en) * | 2012-01-03 | 2016-08-02 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| CN104583189A (zh) | 2012-07-31 | 2015-04-29 | 永信药品工业股份有限公司 | 非晶型的卡巴利他索 |
| TW201827417A (zh) * | 2013-03-04 | 2018-08-01 | 法商安萬特醫藥公司 | 卡巴他賽(cabazitaxel)及其治療轉移性前列腺癌之用途 |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| JP6841772B2 (ja) | 2015-02-17 | 2021-03-10 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 前立腺癌の処置におけるカバジタキセルの使用 |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| WO2018047074A1 (en) | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| US10195214B2 (en) * | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
| WO2018187786A1 (en) * | 2017-04-07 | 2018-10-11 | La Jolla Institute For Allergy And Immunology | Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5005588A (en) | 1989-10-13 | 1991-04-09 | David Rubin | Method for increasing tumor sensitivity to chemotherapy |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| ZA94128B (en) | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
| FR2732340B1 (fr) | 1995-03-27 | 1997-04-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
| FR2745814B1 (fr) | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| US6346543B1 (en) | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| EP1105119A2 (en) | 1998-08-20 | 2001-06-13 | Aventis Pharma S.A. | New use of taxoid derivatives |
| US6403634B1 (en) | 1999-01-13 | 2002-06-11 | Aventis Pharma S.A. | Use of taxoid derivatives |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| SI1493556T1 (sl) | 2003-07-02 | 2006-02-28 | Scheuten Glasgroep Bv | Postopek za pripravo protipozarne zasteklitve |
| EP1498120A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| GB0425854D0 (en) | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
| US20090226894A1 (en) | 2004-12-08 | 2009-09-10 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
| EP1700596A1 (en) | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| FR2922107B1 (fr) | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | Nouvelles compositions a base de taxoides |
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| EP2177630A1 (en) * | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| BRPI1014854A2 (pt) | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
| FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| CA2774015A1 (en) | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| BR112012011457A2 (pt) | 2009-10-29 | 2016-05-03 | Aventis Pharma Sa | uso antitumoral de cabazitaxel. |
| ES2621613T3 (es) | 2009-11-04 | 2017-07-04 | Emcure Pharmaceuticals Limited | Un proceso mejorado para la preparación de derivados de taxano |
| EP2503888A4 (en) | 2009-11-23 | 2015-07-29 | Cerulean Pharma Inc | POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION |
| EP2556166A1 (en) | 2010-04-08 | 2013-02-13 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| WO2011130317A2 (en) | 2010-04-13 | 2011-10-20 | Amplyx Pharmaceuticals Inc. | Therapeutic agents having reduced toxicity |
| JP5975983B2 (ja) | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 固形腫瘍を処置するための方法 |
-
2010
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active IP Right Grant
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en active Application Filing
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
-
2012
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
-
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
-
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
-
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
-
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
-
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
-
2023
- 2023-07-20 US US18/224,122 patent/US20240139146A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201810928SA (en) | Novel antitumoral use of cabazitaxel | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| IN2012DN02081A (es) | ||
| MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MX352892B (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| PH12015501088A1 (en) | Dimeric compounds | |
| MX2012012523A (es) | Lactonas esteroideas anticancerigenas insaturadas en la posicion 7(8). | |
| EA201200190A1 (ru) | Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
| MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
| TN2015000378A1 (en) | Cabazitaxel and its use for treating metastatic prostate cancers | |
| WO2012006563A3 (en) | Novel daidzein analogs as treatment for cancer | |
| NZ593169A (en) | Anticancer compounds | |
| MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. | |
| CO6531492A2 (es) | Nuevo uso antitumoral de cabazitaxel | |
| DOP2012000118A (es) | Nuevo uso antitumoral de cabazitaxel | |
| WO2013070933A3 (en) | Compositions and methods for the treatment of prostate carcinoma | |
| TN2012000552A1 (en) | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative | |
| NZ594996A (en) | Cholestanol derivative for combined use | |
| PH12014501794A1 (en) | New pediatric uses of cabazitaxel | |
| TN2014000342A1 (en) | New pediatric uses of cabazitaxel | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |